Contrast agent developer Palatin Technologies has raised $11.5 million through the private placement of securities to institutional and accredited investors. The Cranbury, NJ-based firm said it would use the proceeds primarily to advance the development of its LeuTech infection imaging agent and further development of its PT-141 drug for the treatment of male and female sexual dysfunction.
By AuntMinnie.com staff writersNovember 20, 2002
Related Reading
Palatin’s revenues down, losses up in fiscal 2002, October 1, 2002
Palatin adds to war chest, August 2, 2002
Palatin, Mallinckrodt restructure deal, May 15, 2002
Palatin raises $11 million, November 12, 2001
LeuTech to be tested for anthrax detection utility, November 5, 2001
Copyright © 2002 AuntMinnie.com
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)
